NCT04368884

Brief Summary

A large number of Health Care Workers (HCWs) would be potentially getting exposed to COVID19. Some of them would be asymptomatic or may get subclinical symptoms. Our HCW would have higher exposure and possibly higher seroconversion either symptomatic or with clinical symptoms than the general population. This study is aimed to understand the rate of seroconversion states at different stages of exposure. It is crucial to collect baseline immune status and the early immunological changes that might occur in asymptomatic or symptomatic health care workers and to compare that with the suspected or confirmed cases by following them for six weeks.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 22, 2020

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

April 29, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 30, 2020

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2021

Completed
Last Updated

July 22, 2020

Status Verified

July 1, 2020

Enrollment Period

1.2 years

First QC Date

April 29, 2020

Last Update Submit

July 20, 2020

Conditions

Keywords

SeroconversionHealthcare WorkersCOVID-19

Outcome Measures

Primary Outcomes (1)

  • Development of antibodies

    Samples will be assessed for the presence of IgG and IgM

    4-8 weeks

Study Arms (3)

Healthcare workers

The healthcare workers who are being tested for COVID-19 would be included in this group

OPD patients

Individuals outside from the hospital who are coming for the COVID-19 testing will be included in this group

IPD COVID-19 cases

Admitted positive cases of COVID-19 in the hospital will be included in this group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All employees of Max Hospital, Saket and Smart, New Delhi, who are coming to the hospital, working in the COVID ward or the nearby wards, and who would agree to participate will be recruited in this study including those who are being tested in suspicion of COVID-19. Samples and data of the COVID positive patients admitted in the hospital will also be collected. OPD patients coming to the hospital for COVID-19 testing will be one of the study subsets.

You may qualify if:

  • Healthcare workers of Max Hospital, irrespective of age and gender OR
  • COVID-19 positive patients admitted in the hospital OR
  • Out-patients getting tested for COVID-19

You may not qualify if:

  • Refusal to give informed consent, or contraindication to venipuncture.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Max Super Speciality Hospital, A Unit of Devki Devi Foundation

New Delhi, National Capital Territory of Delhi, 110017, India

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum and plasma samples are being stored at -70C

MeSH Terms

Conditions

COVID-19HIV Seropositivity

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesHIV InfectionsBlood-Borne InfectionsCommunicable DiseasesSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Study Officials

  • Sujeet Jha, MRCP (U.K)

    Max Healthcare Institute Ltd.

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sujeet Jha, MRCP (U.K)

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 29, 2020

First Posted

April 30, 2020

Study Start

April 22, 2020

Primary Completion

June 30, 2021

Study Completion

July 30, 2021

Last Updated

July 22, 2020

Record last verified: 2020-07

Locations